NCT07918898
Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Notable Recruitment opened
- Start date changed from estimate of Oct 29, 2026 to Nov 2, 2026
- Study sites: 0 to 1
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
AUCIAsp,0-6h
Timeframe: 0-6 hours after dosing
AUC GZR33, 0-24h
Timeframe: 0-24 hours after dosing
Secondary (3)
AUCGZR33, 0-∞
AUC IAsp, 0-∞
Incidence of adverse events
Arms and interventions
GZR101 80 InjectionExperimental
GZR33 Injection + Insulin Aspart InjectionExperimental
Drugs: GZR101 80 Injection, GZR33 Injection, Insulin Aspart Injection
Sites
1 site in 1 country
- Medical Ethics Committee of Bishan Hospital of ChongqingChongqing, China